Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: A West Japan Thoracic Oncology Group (WJTOG) study

Investigational New Drugs

Volumn 25, Issue 4, 2007, Pages 377-383

  Takeda, Koji ^a   Takifuji, Nobuhide ^a   Negoro, Shunichi ^b   Furuse, Kiyoyuki ^c   Nakamura, Shinichiro ^d   Takada, Yoshiki ^b   Hoso, Takanobu ^e   Hayasaka, Shinichi ^f   Nakano, Takashi ^g   Araki, Jun ^h   Senba, Hiroshi ⁱ   Iwami, Fumiyuki ^j   Yamaji, Yasufumi ^k   Fukuoka, Masahiro ^l   Ikegami, Harumichi ^d  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e WAKAYAMA ROSAI HOSPITAL   (Japan)

^f KUMAMOTO CHUO HOSPITAL   (Japan)

^g HYOGO COLLEGE OF MEDICINE   (Japan)

^h Sasebo Shiritsu Sogo Hospital   (Japan)

ⁱ National Hospital Organization   (Japan)

^j Minami Kyushu Hospital   (Japan)

^k Mitoyo General Hospital   (Japan)

^l KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Amrubicin; Anthracycline; Non small cell lung cancer; Phase II study

Indexed keywords

9 AMINOANTHRACYCLINE; AMRUBICIN; ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CYTOLOGY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOLOGY; HUMAN; INCIDENCE; LARGE CELL CARCINOMA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; REPEATED DRUG DOSE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANEMIA; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; JAPAN; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 34250684584     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9039-6     Document Type: Article

References (23)

1. Ishizumi K, Ohashi N, Tanno N (1987) Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem 52:4477-4485
2. Tani N, Yabuki M, Komuro S, Kanamaru H (2005) Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica 35:1121-1133
3. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89:1067-1073
4. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M (1989) Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 80:69-76
5. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 89:1055-1060
6. Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M (1989) Toxicological aspects of a novel 9-aminoanthracyline, SM-5887. Jpn J Cancer Res 80:77-82
7. Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin. Invest New Drugs 15:219-225
8. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T (1998) Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in dogs. Invest New Drugs 16:121-128
9. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T (1998) A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89:1229-1238
10. Hiraki S, Shinkai T, Furuse K, Fukuoka M, Ohnoshi T, Kimura I (1993) A phase II study of SM-5887, a novel 9-aminoanthracycline, for non-small-cell lung cancer. Proceedings of the 18th international congress of chemotherapy 866-867
11. Sugiura T, Ariyoshi Y, Negoro S, Nakamura N, Ikegami H, Takada M, Yana T, Fukuoka M (2005) Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer. Invest New Drugs 23:331-337
12. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1999) Evaluation of amrubicin with a 5 day administration schedule in a mouse model. Jpn J Cancer Chemother 26:1305-1312
13. Cortes EP, Takita H, Holland JF (1974) Adriamycin in advanced bronchogenic carcinoma. Cancer 34:518-525
14. Sawa T, Yana T, Takada M, Sugiura T, Kudoh S, Kamei T, Isobe T, Yamamoto H, Yokota S, Katakami N, Tohda Y, Kawakami A, Nakanishi Y, Ariyoshi Y (2006) Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial. Invest New Drugs 24:151-158
15. Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28:101-130
16. World Health Organization (1979) Handbook for Reporting Results of Cancer Treatment (WHO Offst Publication No. 48). World Health Organization, Geneva, Switzerland
17. Kaplan WH, Meier P (1952) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:583-612
18. Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 11:1866-1872
19. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP (1993) Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 342:19-21
20. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
21. Ginsberg RJ, Vokes EE, Raben A (2001) Non-small cell lung cancer. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott Williams and Wilkins, Philadelphia, pp 925-983
22. Bunn PA, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 5:1087-1100
23. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, Nishiwaki Y, Yokota S, Kawahara M, Saijo N, Fukuoka M, Aritoshi Y (2005) Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 16:430-436